NBIX:NASDAQ
Neurocrine Biosciences, Inc
$ 142.44
arrow_upward
+0.84%(+1.19) 1D
$ 142.44
0.00% (0.00)
bedtimeAfter hours
Closed: 10-р сарын 9, 16:00:00 (GMT-4) · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NBIX...
Open
$ 141.33
High
$ 143.55
Low
$ 140.02
Mkt. cap
14.48 тэрбум
Avg. vol.
1.28 сая
Volume
1.02 сая
P/E ratio
20.88
52-wk high
$ 186.12
52-wk low
$ 122.14
EPS
$ 6.82
Beta
0.40
Shares outstanding
101.65 сая
No. of employees
2 мян
Open
$ 141.33
High
$ 143.55
Low
$ 140.02
Mkt. cap
14.48 тэрбум
Avg. vol.
1.28 сая
Volume
1.02 сая
P/E ratio
20.88
52-wk high
$ 186.12
52-wk low
$ 122.14
EPS
$ 6.82
Beta
0.40
Shares outstanding
101.65 сая
No. of employees
2 мян
News stories
From web sources and news partners
Zacks
·
13 цагийн өмнө
4 CNS Drug Stocks Worth Watching This World Mental Health Day
Profile
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
About Neurocrine Biosciences, Inc
CEOKevin C. Gorman
Employees2.5 мян
Founded1992
HeadquartersСан-Диего, Калифорни, Америкийн Нэгдсэн Улс
Sector-
Websiteneurocrine.com